APL-5125 (Gastrointestinal Cancers) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.
What is the Condition Being Studied?
Gastrointestinal Cancers
Who Can Participate in the Study?
Adults ages 18+ who have locally advanced or metastatic tumors of one of the following types:
- Colorectal carcinoma
- Cholangiocarcinoma
- Appendiceal adenocarcinoma
For more information about this study, contact the study team at 919-668-1861.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take the study drug, APL-5125, by mouth every day
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Study Details
Full Title
[AP10CP01] A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults with Selected Advanced Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00115529
NCT:
NCT06399757
Phase
Phase
I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu